SOC2006
20 Apr 2022
SOC2006
NCT04446260
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subject
Jiangsu HengRui Medicine Co.
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-09-03 |
Anticipated End Date | 2023-12-01 |
Hospital | Southern Oncology Clinical Research Unit |
---|---|
Clinical Trial Coordinator | Meggan O'Riley |
Meggan.ORiley@socru.org.au | |
Phone | 0491 679 039 |
Principal Investigator | Dr Amitesh Roy |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs